Deepinder Goyal’s Temple Reportedly Doubles Valuation to $375M

Consumer-health wearable startup Temple has reportedly reached a $375 million valuation through an ESOP liquidity programme, up from about $190 million. The company is preparing a broader launch of its metabolic-monitoring device, with Ethereal Machines and Zetwerk supporting manufacturing.

— Source publishedMon, 27 Jul, 2026, 15:22 IST·First seen Mon, 27 Jul, 2026, 15:26 IST·Source Inc42 · Buzz

What happened

Deepinder Goyal’s consumer-health wearable startup Temple reportedly doubled its valuation to $375 million through an ESOP liquidity programme. The early-access

Key facts

  • $375 Mn valuation
  • $190 Mn previous valuation
  • $54 Mn seed funding
  • 20 eligible employees
  • 200-220 employee workforce
  • Up to 25% of vested ESOPs
  • ~$500 Mn indicated next-round valuation
  • 28% founder ownership
  • ~10% employee ESOP ownership

Why this matters

Temple’s broader launch plans and manufacturing support from Ethereal Machines and Zetwerk make it a more credible strategic partner or target for companies seeking exposure to preventive health, wearables, and consumer data platforms.

What to watch

  • Official confirmation of the $375M valuation, investor composition, and terms of the ESOP liquidity programme.
  • Launch timing, device price, geography, waitlist conversion, and initial delivery volumes.
  • Evidence of recurring revenue, subscription attach rates, retention, and repeat engagement after the first 90 to 180 days.
  • Manufacturing capacity, defect rates, delivery lead times, and dependence on Ethereal Machines and Zetwerk.
  • Clinical studies, regulatory positioning, accuracy claims, and any scrutiny of health or diagnostic marketing language.
  • Partnerships with employers, insurers, clinics, nutrition companies, or consumer-health platforms.
  • Competitive responses from continuous glucose monitoring companies, smart-ring makers, fitness wearables, and preventive-health startups.
  • Prioritize manufacturing yield, quality control, and service readiness before broad demand-generation spending.
  • Publish credible validation on measurement accuracy, user outcomes, and how insights translate into behavior change.
  • Use the ESOP liquidity event to retain key engineering, hardware, clinical, and growth talent while preserving cash for launch execution.
  • Build subscription, coaching, or clinician-led offerings that increase recurring revenue beyond one-time device sales.
  • Pursue selective employer, insurer, clinic, and wellness-channel pilots to lower customer-acquisition costs and test willingness to pay.
  • Prepare clear data-privacy, consent, and health-claim policies to avoid regulatory or reputational friction as adoption grows.

Also reported by